Back to results
US 5,965,521 AGranted
Pulsatile delivery of leptin receptor ligands
AssigneeEli Lilly and Company
InventorsThomas W. Stephens, Mark L. Heiman, Jose F. Caro
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeEli Lilly and Company
InventorsThomas W. Stephens, Mark L. Heiman, Jose F. Caro
Estimating the term…
This invention provides a method for optimizing the administration of leptin receptor ligands to a mammal in need of such treatment. More specifically, this invention provides an improved method of delivering leptin receptor ligands to a mammal in need of such treatment comprising pulsatile or peak delivery of leptin receptor ligands to treat obesity and related conditions, including hyperglucocorticoidinemia, fertility or delayed puberty, and/or growth hormone deficiencies.
An improved method of delivering leptin receptor ligands to a mammal in need of such treatment comprising peak delivery of leptin receptor ligands at the time of normal circadian peak of leptin release to treat obesity, hyperglucocorticoidinemia, fertility or delayed puberty, or growth hormone deficiencies.
Dependencies are inferred from the claim text.
Drawings are temporarily unavailable. Open the PDF at USPTO
No related US applications are recorded in the indexed filing history.
Hormones: obesity-gene products, e.g. leptin
Drugs for disorders of the metabolism: anorexiants; Antiobesity agents
Drugs for disorders of the endocrine system
Drugs for disorders of the endocrine system: of the sex hormones
Term ended 25 Feb 2017 (estimated)
USPTO file history isn’t available for this patent, so only indexed dates are shown.
1. Field of the Invention
This invention relates generally to a method for optimizing the administration of leptin receptor ligands to a mammal in need of such treatment. More specifically, this invention relates to an improved method of delivering leptin receptor ligands to a mammal in need of such treatment comprising pulsatile or peak delivery of leptin receptor ligands to treat obesity and related conditions, including hyperglucocorticoidemia, fertility or delayed puberty, and/or growth hormone deficiencies.
2. Description of the Related Art
Having now generally described this invention, the same will be better understood by reference to certain specific examples, which are included herein for purposes of illustration only and are not intended to be limiting of the invention or any embodiment thereof, unless so specified.
In the present experiment we demonstrate ultradian oscillatory patterns of leptin secretion in humans with approximate frequency of four hours.
MATERIALS AND METHODS